Increase in \textit{Clostridium difficile}–related Mortality Rates, United States, 1999–2004

Matthew D. Redelings,* Frank Sorvillo,*† and Laurene Mascola*

Reported mortality rates from \textit{Clostridium difficile} disease in the United States increased from 5.7 per million population in 1999 to 23.7 per million in 2004. Increased rates may be due to emergence of a highly virulent strain of \textit{C. difficile}. Rates were higher for whites than for other racial/ethnic groups.

\textit{Clostridium difficile} is an anaerobic, gram-positive bacillus that can cause considerable disease, including diarrhea, colitis, and septicemia, resulting in death (1). \textit{C. difficile}–associated disease (CDAD) primarily affects persons $\geq$65 years. Risk factors include residence in hospitals and long-term care facilities and the use of antimicrobial medications (1–3). Incidence of CDAD has been increasing, and severe cases are becoming more common (4,5). These changes in the incidence and severity of CDAD may be associated with the emergence of a more virulent strain of \textit{C. difficile} bacteria (5,6). Death rates associated with \textit{C. difficile} were reported to be increasing from 1999 to 2002 in the United States and from 2001 to 2005 in England and Wales (7,8). However, no trend analysis was conducted to evaluate the rate of increase. We incorporated mortality data for the United States through the year 2004 to conduct trend analyses of CDAD-related deaths and to examine demographic characteristics and coexisting conditions reported in deaths from \textit{C. difficile} infection.

The Study

CDAD-related deaths were identified by using multiple cause-of-death data from national mortality records for 1999–2004. CDAD-related deaths were defined as all deaths for which the underlying cause of death or any of the contributing causes of death included the International Classification of Diseases, 10th revision (ICD-10) code A04.7 (enterocolitis due to \textit{C. difficile}). Information about the size and demographic breakdown of the US population for each year during 1999–2004 was obtained from censal and intercensal year estimates with bridged race data (9,10). Age-adjusted mortality rates were calculated by using the age distribution of the 2000 US population as a standard (11). The US population was divided into 5 racial/ethnic categories: white, Hispanic, Asian/Pacific Islander, black, and American Indian/Alaska Native.

During 1999–2004, CDAD was reported as a cause of death for 20,642 persons. CDAD was reported as the underlying cause for 12,264 (59%) of these deaths. A total of 3,256 deaths were reported related to all other intestinal infectious diseases combined (ICD-10 codes A00 to A09, excluding A047) over the same period. The median age of death for CDAD patients was 82 years. Age-adjusted mortality rates from CDAD were slightly higher for men than for women (Table) and were higher for whites than for any other racial/ethnic group. Most CDAD-related deaths occurred in hospitals ($n = 16,557$, 80%); 1,634 (8%) occurred in long-term care facilities, and 2,027 (10%) occurred at home.

Common coexisting conditions for CDAD-related deaths included septicemia ($n = 7,654$, 37%), renal failure ($n = 4,786$, 23%), pneumonia ($n = 3,430$, 17%), urinary tract infection ($n = 1,496$, 7%), and anemia ($n = 785$, 4%). HIV was reported for 81 CDAD-related deaths (<1%). However, among the 697 deaths reported in persons 25–54 years of age, HIV was reported for 72 (10%).

The overall rate of \textit{C. difficile}–related deaths during the study period was 12.2 deaths per million population. Mortality rates related to CDAD increased during the study period (Figure), rising from 5.7 deaths per million population in 1999 to 23.7 deaths per million population in 2004. Poisson regression estimates showed mortality rates increased by 35% per year (coefficient = 0.30, standard error = 0.004, 95% confidence interval = 0.29–0.31) during the study period.

Conclusions

Due to the inclusion of CDAD-related deaths when CDAD was not reported as the underlying cause of death, reported death rates in this study were higher than those published in an earlier analysis of CDAD-related deaths in the United States (7). \textit{C. difficile} is a cause of a substantial and increasing proportion of deaths in the United States and may be underrecognized as a cause of death. Little attention has been paid to \textit{C. difficile} prevention; media and public health awareness efforts have focused largely on the prevention of disease from other intestinal pathogens such as \textit{Escherichia coli} or \textit{Salmonella} spp. However, the incidence of deaths from \textit{C. difficile} is greater than the extent of deaths from all other intestinal infectious diseases combined. \textit{C. difficile}–related mortality rates were higher

\*Los Angeles County Department of Public Health, Los Angeles, California, USA; and †University of California Los Angeles–School of Public Health, Los Angeles, California, USA
for whites than for other racial/ethnic groups. Racial/ethnic differences in insurance status and access to care (12) may render elderly whites more likely to receive treatment with antimicrobial drugs that put them at risk for *C. difficile* infection. However, genetic or other factors may also be involved, and further research is needed to determine the causes of racial/ethnic differences in *C. difficile*-related deaths.

Previous research showed increases in CDAD-related mortality rates in the United States until 2002 (7,8). This analysis estimates the rate of increase at 35% per year, and shows that mortality rates continued to increase at least until 2004. Increases in incidence and deaths from CDAD may be associated with the emergence of a new and more virulent strain of *C. difficile* (5). The emergence of virulent strains of *C. difficile* makes continued assessment of mortality statistics important.

Infection with *C. difficile* is associated with recent use of antimicrobial medications and with residence in hospitals. Most CDAD cases are acquired in healthcare settings (1), and as many as 90% of cases may be associated with antimicrobial drug use (2,3). High *C. difficile* death rates call attention to the importance of proper infection control practices in hospitals and long-term care facilities and the judicious use of antimicrobial medications. Further research is needed to explore current questions concerning which antimicrobial medications, if any, will lead to CDAD (13,14).

Infections such as septicemia, pneumonia, and urinary tract infections were commonly reported in conjunction with *C. difficile*-related deaths. For some of these patients, the administration of antimicrobial medications to treat infections from other pathogens may have paved the way for infection with *C. difficile*. However, other risk factors are known, so that in many cases the careful use of antimicrobial agents may not be enough to prevent *C. difficile* infection. HIV infection was only reported in a small fraction of CDAD–related deaths. However, immunosuppression and the use of prophylactic antimicrobial drugs in persons with AIDS may increase the risk for CDAD (15), and the effects of HIV should not be overlooked. In persons 25–54 years

| Demographic group          | *C. difficile*–related deaths, no. (%) | Age-adjusted mortality rate/million population |
|---------------------------|---------------------------------------|-----------------------------------------------|
| Sex                       |                                       |                                               |
| Female                    | 12,468 (60)                           | 11.8                                          |
| Male                      | 8,174 (40)                            | 12.7                                          |
| Race/ethnicity            |                                       |                                               |
| White                     | 18,534 (90)                           | 12.9                                          |
| Hispanic                  | 602 (3)                               | 7.2                                           |
| Black                     | 1,304 (6)                             | 9.3                                           |
| Asian/Pacific Islander    | 139 (1)                               | 3.5                                           |
| American Indian/Alaska Native | 63 (<1)       | 7.9                                           |
| Age group, y              |                                       |                                               |
| <1                        | 17 (<1)                               | 0.7*                                          |
| 1–4                       | 11 (<1)                               | 0.1*                                          |
| 5–14                      | 12 (<1)                               | 0.1*                                          |
| 15–24                     | 24 (<1)                               | 0.1*                                          |
| 25–34                     | 62 (<1)                               | 0.3*                                          |
| 35–44                     | 171 (1)                               | 0.6*                                          |
| 45–54                     | 464 (2)                               | 2.0*                                          |
| 55–64                     | 1,159 (6)                             | 7.6*                                          |
| 65–74                     | 3,238 (16)                            | 29.3*                                         |
| 75–84                     | 7,859 (38)                            | 104.0*                                        |
| >85                       | 7,623 (37)                            | 287.1*                                        |
| Total                     | 20,642                                | 12.2                                          |

*This statistic is not age-adjusted because it only pertains to 1 age group.*
of age, in whom HIV infection is most common, HIV infection was reported in approximately one tenth of CDAD-related deaths. Thus, HIV can considerably increase *C. difficile* death rates for demographic groups in which HIV prevalence is high.

Death certificate data may underrepresent the extent of CDAD-related deaths. This analysis was limited to deaths in which ICD-10 code A047 (enterocolitis due to *C. difficile*) was mentioned and may have failed to capture CDAD-related deaths in which colitis was not present. In addition, death certificate data may be affected by reporting error. Supplemental information such as decedents’ medical histories was unavailable. No data were available regarding which strains of *C. difficile* were responsible for reported CDAD–related deaths.

*C. difficile* is an underrecognized cause of severe illness and death. This analysis underscores the importance of CDAD as a public health problem and the increasing incidence of CDAD-related deaths in the United States.

Mr Redelings is an epidemiology analyst with the Los Angeles County Department of Public Health. He previously served as a humanitarian worker in Sudan. His current research interests include the epidemiology of gastrointestinal infections and the prevention of disease in refugee situations.

References

1. Kelly CP, Pothoulakis C, LaMont TJ. *Clostridium difficile* colitis. N Engl J Med. 1994;330:257–62.
2. Bignardi GE. Risk factors for *Clostridium difficile* infection. J Hosp Infect. 1998;40:1–15.
3. Barbut F, Petit JC. Epidemiology of *Clostridium difficile*–associated infections. Clin Microbiol Infect. 2001;7:405–10.
4. McDonald L, Banerjee S, Jernigan DB. Increasing incidence of *Clostridium difficile*–associated disease in US acute care hospitals, 1993–2001. Presented at the 14th Annual Scientific Meeting of the Society for Healthcare Epidemiology in America; Apr 17–20, 2004; Philadelphia. Abstract 67.
5. Pepin J, Valiquette L, Alary ME. *Clostridium difficile*–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–72.
6. Kuiper EJ, Coignard B, Tull P, ESCMID Study Group for *Clostridium difficile*; EU Member States; and European Centre for Disease Prevention and Control (ECDC). Emergence of *Clostridium difficile*–associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18.
7. Wysowski DK. Increase in deaths related to enterocolitis due to *Clostridium difficile* in the United States, 1999–2002. Public Health Rep. 2006;121:361–2.
8. Deaths involving MRSA and *Clostridium difficile* continue to rise. Health Stat Q. 2007; Press release: 1–3.
9. National Center for Health Statistics. Bridged-race intercensal estimates of the July 1, 1990–July 1, 1999, United States resident population by county, single-year of age, sex, race, and Hispanic origin. [cited 2007 Mar 30]. Available from http://www.cdc.gov/nchs/about/major/dvs/popbridge/databoc.htm#inter1
10. National Center for Health Statistics. Estimates of the July 1, 2000–July 1, 2004, United States resident population from the vintage 2003 postcensal series by year, county, age, sex, race, and Hispanic origin. [cited 2007 Mar 30]. Available from http://www.cdc.gov/nchs/about/major/dvs/popbridge/databoc.htm#inter1
11. Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998;47:1–16, 20.
12. Adams PF, Barnes PM. Summary health statistics for the U.S. population: National Health Interview Survey, 2004. Vital Health Stat 10. 2006;229:1–104.
13. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rohon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause *Clostridium difficile*–associated disease? Antimicrob Agents Chemother. 2006;50:3216–9.
14. Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM, Killgore G, et al. Outbreak of *Clostridium difficile* infection in a long-term care facility; association with gatifloxacin use. Clin Infect Dis. 2004;38:640–5.
15. Sanchez TH, Brooks JT, Sullivan PS, Juhasz M, Mintz E, Sworkin MS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992–2002. Clin Infect Dis. 2005;41:1621–7.

Address for correspondence: Matthew D. Redelings, 313 N Figueroa 127, Philadelphia. Abstract 67.

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.